-
Treating rheumatoid arthritis CRISPR edits "smart cells" to show therapeutic potential
Time of Update: 2021-10-23
In the RA mouse model, once inflammation occurs, the implanted "smart" cells will automatically sense the changes in the level of endogenous inflammatory cytokines and respond to deliver a corresponding therapeutic level.
-
Treat chronic hepatitis B! Zhengda Tianqing TQA3605 tablets were first approved for clinical use
Time of Update: 2021-10-23
However, according to statistics, China's HBV infection are still about 70 million cases, of which, approximately 20 million patients with chronic hepatitis B -3000 ten thousand cases .
Approximately 300,000 people die from hepatitis B-related cirrhosis and liver cancer each year, accounting for 50% of hepatitis B-related deaths worldwide .
-
Innovative androgen therapy for the treatment of male NASH patients reaches phase 2 clinical endpoint
Time of Update: 2021-10-23
On August 25, 2021, Lipocine announced that its investigational therapy LPCN 1144 has obtained positive results in the Phase 2 proof-of-concept clinical trial LiFT for the treatment of male patients with non-alcoholic steatohepatitis (NASH) .
-
The new crown vaccine booster is coming, and the antibodies produced will have stronger endurance
Time of Update: 2021-10-23
For example, on September 17, news from a press conference in Zhejiang Province showed that in the near future, the strengthening of immunization for key populations will be carried out in an orderly manner in accordance with the unified arrangements of the country .
-
860 studies analyze that these eating habits really increase the risk of cancer
Time of Update: 2021-10-23
The study showed that drinking alcohol is associated with increased risk of breast, colorectal, esophageal, head and neck cancer, and liver cancer after menopause; dairy products, pure milk, calcium, and whole grains are associated with a reduced risk of colorectal cancer; coffee drinking is associated with liver cancer It is associated with a reduced risk of skin basal cell carcinoma .
-
Phase 3 clinical results of Bayer's "first-in-class" therapy released
Time of Update: 2021-10-23
A few days ago, Bayer announced that its "first-in-class" therapy Kerendia (finerenone), a phase 3 clinical trial FIGARO-DKD in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) The primary end point was reached .
-
The "anti-cancer weapon" they created has brought a safer life to countless women
Time of Update: 2021-10-23
He used the work left by studying EBV that year and contacted some colleagues to ask them to check whether the cervical cancer samples contained HSV-2 DNA, but the results given by the colleagues were negative .
Retrieved September 1st 2021 from https:// HPV vaccines for cancer prevention.
-
Can't lose fat?
Time of Update: 2021-10-23
Weight loss can be particularly difficult when intestinal bacteria slow their own growth, while also breaking down dietary fiber into energy-rich sugars that enter the human blood before being fermented by the microbiota into organic acids .
-
Zhang Feng's team re-published "Science", which is expected to promote the next revolution in genome editing technology
Time of Update: 2021-10-23
In this paper, Professor Zhang Feng's team started from the origin of the CRISPR-Cas system and identified a new type of nuclease in bacteria, which is guided by the RNA encoded by the transposon to a target location to cut DNA .
-
A breakthrough in solving microbial resistance: Harvard develops a broad-spectrum anti-infective vaccine supported by dual technologies
Time of Update: 2021-10-23
(Source: Nature Biomedical Engineering)The research team found that the ciVAX vaccine can rapidly enhance the accumulation and activation of DC at the injection site, and increase the number of different types of T cells in DC, antibody-producing B cells, and draining lymph nodes, thereby generating an effective pathogen-directed immune response .
-
The structure of intestinal flora affects the weight loss effect of low-carbon diet
Time of Update: 2021-10-23
Through prospective, randomized controlled clinical studies, combined with high-throughput sequencing and bioinformatics big data analysis, researchers found that the structure of the intestinal flora is a determinant of the short-term LCD weight loss effect for overweight and obese people .
-
Drinking wolfberry puree frequently, the body can get 5 benefits! After reading the knowledge
Time of Update: 2021-10-23
It contains particularly rich amino acids, lycium barbarum polysaccharides, vitamins and other ingredients, and has strong nutritional, health care and medicinal value to the human body .
-
Two immune combination therapies for the first-line treatment of esophageal cancer and BMS are expected to add additional indications
Time of Update: 2021-10-23
Dual immunotherapy consisting of pimumab; and supplementary biological product license application (sBLA) for a combination therapy consisting of nivolumab combined with fluorouracil and platinum-containing chemotherapy for the first-line treatment of advanced unresectable, recurrent or metastatic Esophageal squamous cell carcinoma (ESCC) .
-
CDK1: Occupies an important site of signal transduction, clinically refers to pancreatic cancer & glioma!
Time of Update: 2021-10-23
1 The functional location of important targets of CDK1 in the cell cycle (see the literature at the end of the article)Disease location: pancreatic cancer & gliomaDisease location: pancreatic cancer & gliomaAt present, the development of clinical indications for CDK1 inhibitors is mainly focused on pancreatic cancer and glioma, especially pancreatic cancer .
-
The treatment of cholangiocarcinoma welcomes new FGFR inhibitors, and currently three types of FGFR inhibitors have been approved
Time of Update: 2021-10-23
3. Infigratinib, an innovative, oral, FGFR-1, 2, 3 selective and potent inhibitor, was approved by the FDA in May 2021 for the treatment of previously treated locally advanced patients with FGFR2 fusion or rearrangement Or patients with metastatic cholangiocarcinoma .
-
Potential "first-in-class" therapy for treating atopic dermatitis obtained clinical proof of concept
Time of Update: 2021-10-23
On September 27, 2021, ASLAN Pharmaceuticals announced that the monoclonal antibody ASLAN004, which targets the IL-13 receptor α1 subunit (IL-13α1), is used in the treatment of moderate to severe atopic dermatitis (AD).
Retrieved September 27, 2021, from https:// en/ASLAN-Pharmaceuticals-Announces-Positive-Data-Conclusively-Establishing-Proof-of-Concept-for-ASLAN004-in-Atopic-Dermatitis.
-
Hengrui Medicine's 1.1 category new drug pyrrotinib new indication listing application is planned to be included in priority review
Time of Update: 2021-10-23
The indication for pyrrotinib's application for marketing is "combined with trastuzumab and docetaxel, suitable for the treatment of epidermal growth factor receptor 2 (HER2) positive early or locally advanced breast cancer neoadjuvant therapy" .
-
Excitatory postsynaptic protein PSD-93 plays an important role in the pathogenesis of depression
Time of Update: 2021-10-23
The reporter learned from the University of Science and Technology of China that Zhou Jiangning’s research group used genetic manipulation of mice, combined with techniques such as behavior, patch clamp, chemical genetics, and in vivo optical fiber recording, and found that: The excitatory postsynaptic protein PSD-93 plays an important role in the pathogenesis of depression .
-
Dupixent in the treatment of infantile eczema patients reaches the phase 3 clinical endpoint
Time of Update: 2021-10-23
The data shows that at the 16th week, compared with the standard treatment, the topical corticosteroid (TCS) was added to the topical corticosteroid (TCS), which significantly reduced the patient's overall disease severity and significantly improved the patient's skin Symptom clearance, itching, and health-related quality of life indicators .
-
Zymo's EZ DNA kit received the CE mark
Time of Update: 2021-10-23
The EZ DNA Methylation-Lightning Kit uses ready-to-use conversion reagents, which simplifies the workflow and can be completed in just over an hour .
“The kit integrates A large number of manual intensive steps required for accurate and complete DNA bisulfite conversion make the originally cumbersome workflow easy to use and ensure consistency .
